These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22125064)

  • 1. Evaluation of rapamycin-induced cell death.
    Galluzzi L; Morselli E; Kepp O; Vitale I; Younes AB; Maiuri MC; Kroemer G
    Methods Mol Biol; 2012; 821():125-69. PubMed ID: 22125064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ; Abraham RT; Yu K
    Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
    Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
    Tirado OM; Mateo-Lozano S; Notario V
    Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
    Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease.
    Santos RX; Correia SC; Cardoso S; Carvalho C; Santos MS; Moreira PI
    J Neurochem; 2011 Jun; 117(6):927-36. PubMed ID: 21447003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition of cell growth by rapamycin through targeting mammalian target of rapamycin signaling pathway in nasopharyngeal carcinoma].
    Li YL; Zhang X; Liu Y; Li SS; Xie L; Zhang N; Liu XB; Tian YQ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Sep; 45(9):765-8. PubMed ID: 21092676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes.
    Vollenbröker B; George B; Wolfgart M; Saleem MA; Pavenstädt H; Weide T
    Am J Physiol Renal Physiol; 2009 Feb; 296(2):F418-26. PubMed ID: 19019920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases.
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2011 Aug; 14(4):437-41. PubMed ID: 21851176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
    Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin protects against dominant negative-HNF1A-induced apoptosis in INS-1 cells.
    Farrelly AM; Kilbride SM; Bonner C; Prehn JH; Byrne MM
    Apoptosis; 2011 Nov; 16(11):1128-37. PubMed ID: 21874357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin: an anti-cancer immunosuppressant?
    Law BK
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rapamycine and mTOR inhibitors: from bench to bedside].
    Pallet N; Beaune P; Legendre C; Anglicheau D
    Ann Biol Clin (Paris); 2006; 64(2):107-15. PubMed ID: 16556521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.
    Stylianou K; Petrakis I; Mavroeidi V; Stratakis S; Vardaki E; Perakis K; Stratigis S; Passam A; Papadogiorgaki E; Giannakakis K; Nakopoulou L; Daphnis E
    Nephrol Dial Transplant; 2011 Feb; 26(2):498-508. PubMed ID: 20709738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR and the differentiation of mesenchymal stem cells.
    Xiang X; Zhao J; Xu G; Li Y; Zhang W
    Acta Biochim Biophys Sin (Shanghai); 2011 Jul; 43(7):501-10. PubMed ID: 21642276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [mTOR, the mammalian target of rapamycin].
    Julien LA; Roux PP
    Med Sci (Paris); 2010 Dec; 26(12):1056-60. PubMed ID: 21187044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis.
    Huo Y; Iadevaia V; Proud CG
    Biochem Soc Trans; 2011 Apr; 39(2):446-50. PubMed ID: 21428917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells.
    Edinger AL; Linardic CM; Chiang GG; Thompson CB; Abraham RT
    Cancer Res; 2003 Dec; 63(23):8451-60. PubMed ID: 14679009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.